Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06133270 | A First Human Dose Study Investigating Safety and Concentration of Study Medicine in the Blood Following Once Daily Oral Dosing of NNC0560-0004 in Healthy Adults. | PHASE1 | COMPLETED | 51 | — | — | Nov 13, 2023 | Jul 4, 2024 | Aug 20, 2025 | 1 | United Kingdom |
Number of events
Number of events
Number of events
| Arm | Type | Description |
|---|---|---|
| NNC0560-0004 | EXPERIMENTAL | The study will be conducted in 3 parts. Participants will be randomized to receive NNC0560-0004 in Part A: Single ascending dose (SAD) Part B: Multiple ascending dose (MAD) No randomisation - only active treatment in Part C: Single dose |
| Placebo (NNC0560-0004) | PLACEBO_COMPARATOR | Participant will be randomized to receive placebo in: Part A: Single ascending dose (SAD) Part B: Multiple ascending dose (MAD) |
| Name | Type | Description |
|---|---|---|
| NNC0560-0004 | DRUG | NNC0560-0004, Oral administration (taken through the mouth) |
| Placebo (NNC0560-0004) | DRUG | Placebo matching NNC0560-0004, Oral administration (taken through the mouth) |
Key inclusion criteria: 1. Female, of non-childbearing potential, or male, both genders aged 18-55 years (both inclusive) at the time of signing informed consent. 2. Body Mass Index (BMI) between 18.5 and 29.9 kg/m\^2 (both inclusive) at screening. 3. Considered to be generally healthy based on the...